View Older Stories View More Recent Stories

Dec 23, 2020 11:31AM Allogene Therapeutics (ALLO) Receives IND Clearance from FDA for ALLO-715 in Combination with Nirogacestat in R/R Multiple Myeloma
Dec 23, 2020 11:30AM Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-715 in Combination with Nirogacestat in Relapsed/Refractory Multiple Myeloma
Dec 23, 2020 11:30AM Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-715 in Combination with Nirogacestat in Relapsed/Refractory Multiple Myeloma
Dec 15, 2020 06:14AM Allogene Therapeutics (ALLO) and Overland Pharmaceuticals Form Joint Venture in Greater China to Develop and Commercialize AlloCAR T Cell Therapies
Dec 15, 2020 06:00AM Allogene Therapeutics and Overland Pharmaceuticals Form Joint Venture in Greater China to Develop and Commercialize AlloCAR T™ Cell Therapies
Dec 15, 2020 06:00AM Allogene Therapeutics and Overland Pharmaceuticals Form Joint Venture in Greater China to Develop and Commercialize AlloCAR T™ Cell Therapies
Dec 7, 2020 10:09AM Allogene Therapeutics (ALLO) Presents Preclinical Findings Supporting ALLO-605, the First Anti-BCMA TurboCAR™ T Cell Therapy, at ASH
Dec 7, 2020 10:00AM Allogene Therapeutics Presents Preclinical Findings Supporting ALLO-605, the First Anti-BCMA TurboCAR™ T Cell Therapy, at the 62nd Meeting of the American Society of Hematology
Dec 7, 2020 10:00AM Allogene Therapeutics Presents Preclinical Findings Supporting ALLO-605, the First Anti-BCMA TurboCAR™ T Cell Therapy, at the 62nd Meeting of the American Society of Hematology
Dec 6, 2020 10:00AM Allogene Therapeutics Presents Preclinical Data on ALLO-316 in Acute Myeloid Leukemia at the 62nd Meeting of the American Society of Hematology
Dec 6, 2020 10:00AM Allogene Therapeutics Presents Preclinical Data on ALLO-316 in Acute Myeloid Leukemia at the 62nd Meeting of the American Society of Hematology
Dec 5, 2020 12:30PM Allogene Therapeutics Reports Positive Initial Results from Phase 1 UNIVERSAL Study of ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 62nd American Society of Hemato
Dec 5, 2020 12:30PM Allogene Therapeutics Reports Positive Initial Results from Phase 1 UNIVERSAL Study of ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 62nd American Society of Hemato
Dec 2, 2020 08:30AM Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020
Dec 2, 2020 08:30AM Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020
Nov 12, 2020 08:30AM Allogene Therapeutics Announces November and December 2020 Virtual Investor Conference Participation
Nov 12, 2020 08:30AM Allogene Therapeutics Announces November and December 2020 Virtual Investor Conference Participation
Nov 4, 2020 09:10AM Allogene Therapeutics (ALLO) Announces Oral Presentation of Initial Results from its Phase 1 Dose Escalation Study of ALLO-715 in Relapsed/Refractory Multiple Myeloma at ASH
Nov 4, 2020 09:03AM Allogene Therapeutics Announces Oral Presentation of Initial Results from its Phase 1 Dose Escalation Study of ALLO-715 in Relapsed/Refractory Multiple Myeloma at the 62nd Annual Meeting of the Ameri
Nov 4, 2020 09:03AM Allogene Therapeutics Announces Oral Presentation of Initial Results from its Phase 1 Dose Escalation Study of ALLO-715 in Relapsed/Refractory Multiple Myeloma at the 62nd Annual Meeting of the Ameri
Nov 4, 2020 07:30AM Allogene Therapeutics Reports Third Quarter 2020 Financial Results
Nov 4, 2020 07:30AM Allogene Therapeutics Reports Third Quarter 2020 Financial Results
Oct 27, 2020 08:30AM Allogene Therapeutics to Report Third Quarter 2020 Financial Results on November 4, 2020
Oct 27, 2020 08:30AM Allogene Therapeutics to Report Third Quarter 2020 Financial Results on November 4, 2020
Oct 15, 2020 08:00AM Allogene Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Advancement of Allogeneic CAR T Therapy (AlloCAR T™)
Oct 15, 2020 08:00AM Allogene Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Advancement of Allogeneic CAR T Therapy (AlloCAR T™)
Oct 1, 2020 08:30AM Allogene Therapeutics Announces October 2020 Virtual Investor Conference Participation
Oct 1, 2020 08:30AM Allogene Therapeutics Announces October 2020 Virtual Investor Conference Participation
Sep 2, 2020 08:30AM Allogene Therapeutics Announces September 2020 Virtual Investor Conference Participation
Sep 2, 2020 08:30AM Allogene Therapeutics Announces September 2020 Virtual Investor Conference Participation
Aug 5, 2020 07:30AM Allogene Therapeutics Reports Second Quarter 2020 Financial Results
Aug 5, 2020 07:30AM Allogene Therapeutics Reports Second Quarter 2020 Financial Results
Jul 28, 2020 08:30AM Allogene Therapeutics to Report Second Quarter 2020 Financial Results on August 5, 2020
Jul 28, 2020 08:30AM Allogene Therapeutics to Report Second Quarter 2020 Financial Results on August 5, 2020
Jul 7, 2020 08:30AM Allogene Therapeutics Adds Immunotherapy Luminaries, Thomas F. Gajewski, M.D., Ph.D., and Stephan Grupp, M.D., Ph.D., to its Scientific Advisory Board
Jul 7, 2020 08:30AM Allogene Therapeutics Adds Immunotherapy Luminaries, Thomas F. Gajewski, M.D., Ph.D., and Stephan Grupp, M.D., Ph.D., to its Scientific Advisory Board
Jul 1, 2020 08:30AM Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the Dutch Research Council’s Stevin Prize
Jul 1, 2020 08:30AM Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the Dutch Research Council’s Stevin Prize
Jun 22, 2020 04:32PM Allogene Therapeutics (ALLO) Highlights Findings Supporting an Allogeneic DLL3 CAR for SCLC & Development of Inducible TurboCAR
Jun 22, 2020 04:30PM Allogene Therapeutics Presents Preclinical Findings Supporting an Allogeneic DLL3 CAR for Small Cell Lung Cancer and Development of an Inducible TurboCAR™ at the American Association for Cancer Rese
Jun 22, 2020 04:30PM Allogene Therapeutics Presents Preclinical Findings Supporting an Allogeneic DLL3 CAR for Small Cell Lung Cancer and Development of an Inducible TurboCAR™ at the American Association for Cancer Rese
Jun 22, 2020 08:34AM Allogene Therapeutics (ALLO) Reports Publication Highlighting Potential for ALLO-819 In Acute Myeloid Leukemia
Jun 22, 2020 08:30AM Allogene Therapeutics Announces Publication Highlighting Potential for ALLO-819 In Acute Myeloid Leukemia
Jun 22, 2020 08:30AM Allogene Therapeutics Announces Publication Highlighting Potential for ALLO-819 In Acute Myeloid Leukemia
Jun 3, 2020 08:30AM Allogene Therapeutics Announces June 2020 Virtual Investor Conference Participation
Jun 3, 2020 08:30AM Allogene Therapeutics Announces June 2020 Virtual Investor Conference Participation
May 29, 2020 08:12AM Allogene Therapeutics (ALLO) with Collaborator Servier Reports Positive Results from its Phase 1 ALPHA Study of ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma at ASCO
May 29, 2020 08:00AM Allogene Therapeutics, with Collaborator Servier, Reports Positive Results from its Phase 1 ALPHA Study of ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Onco
May 29, 2020 08:00AM Allogene Therapeutics, with Collaborator Servier, Reports Positive Results from its Phase 1 ALPHA Study of ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Onco
May 26, 2020 04:30PM Allogene Therapeutics Announces Webinar to Review Initial ALLO-501 Phase 1 Data on May 29, 2020
View More Recent Stories View Older Stories